Our Platform Technologies

Eyam’s ‘Next Generation’ technologies overcome current mRNA platform limitations with competitive advantages in design, delivery, manufacturing and production.

Our Platform Technologies

Eyam’s ‘Next Generation’ technologies overcome current mRNA platform limitations with competitive advantages in design, delivery, manufacturing and production.

What are mRNA vaccines?

mRNA vaccines protect against infectious and non-infectious diseases by introducing a piece of mRNA that corresponds to the protein that is being targeted.

This triggers an immune response by the body through the production of targeting antibodies.

mRNA vaccines teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies.

Eyam’s Advantages

  • Novel, Dual Promoter Self-Amplifying Technology.
  • Antigen Expression for more than 42 Days.
  • Novel and Proprietary Vectors.
  • Freeze Drying Capability for Longer Storage and better stability.
  • Overcomes the need for Lipid Nanoparticle Encapsulation.

SELF-AMPLIFYING TECHNOLOGY

Gemini: Amplifying Expression

  • With embedded self-amplifying technology, mRNA enters the cell and creates multiple copies of the protein being targeted.
  • These proteins are then presented to the host’s immune system, which recognizes that the protein is foreign and produces antibodies against it.
  • Once produced, antibodies remain in the body, even after the body has rid itself of the pathogen, creating a quick response if exposed again.
  • In trials, Gemini registered protein expression of more than 42 days.

SELF-AMPLIFYING VACCINE TECHNOLOGY

Gemini: Amplifying Expression

  • With embedded self-amplifying technology, mRNA enters the cell and creates multiple copies of the protein being targeted.
  • These proteins are then presented to the host’s immune system, which recognizes that the protein is foreign and produces antibodies against it.
  • Once produced, antibodies remain in the body, even after the body has rid itself of the pathogen, creating a quick response if exposed again.
  • In trials, Gemini registered protein expression of more than 42 days.

MACHINE LEARNING INFORMED DESIGN

Advanced Targeting with the Jennerator Platform

  • The Jennerator Bioinformatics Platform uses a set of machine learning techniques to select better disease fighting targets.
  • The Jennerator uses as input potential antigen targets, sequenced data capturing variability of the virus, and the population structure of the immune system as input.

Optimization:

  • The platform optimizes vaccine and therapeutic designs by utilizing data from preclinical trials to learn and enhance antigen targets.
  • The output of the Jennerator optimizes constructs with multiple antigen targets to create universal vaccines and more effective therapeutics.

MACHINE LEARNING INFORMED DESIGN

Advanced Targeting with the Jennerator Platform

  • The Jennerator Bioinformatics Platform uses a set of machine learning techniques to select better disease fighting targets.
  • The Jennerator uses as input potential antigen targets, sequenced data capturing variability of the virus, and the population structure of the immune system as input.

Optimization:

  • The platform optimizes vaccine and therapeutic designs by utilizing data from preclinical trials to learn and enhance antigen targets.
  • The output of the Jennerator optimizes constructs with multiple antigen targets to create universal vaccines and more effective therapeutics.

Eyam’s low dose vaccines and therapeutics offer the potential to address a broad array of diseases with reduction in manufacturing time and cost.

Eyam’s low dose vaccines and therapeutics offer the potential to address a broad array of diseases with reduction in manufacturing time and cost.

Low Dose

Because of Eyam’s self amplifying technology, the Gemini Platform requires a much lower dose than other platforms.

Safety

Combining Gemini’s low dosage with the ability to bypass the need for LNPs creates a platform with significantly less inflammation than first generation mRNA platforms.

Efficacy

Up to 10x longer antigen expression for a greater immune response.

Platform Stability

Gemini has the ability to be frozen and thawed several times and lyophilized for longer storage and easier shipping.

Elimination LNPs

Gemini uses naked mRNA, bypassing the need for LNPs while still delivering greater stability at higher temperatures, strong protein expression, and impressive immunogenicity.

 

Eyam’s Pipeline

 

Eyam’s Pipeline